No, Amgen, Sanofi's New Cholesterol Drugs Aren't Going To Cost $150 Billion A Year
In an article on the Health Affairs blog 4 CVS executives speculate that the new cholesterol lowering PCSK9 inhibitors from Amgen and Sanofi might achieve yearly sales of $150 billion or even higher. I think these numbers are a bit silly. But first let’s take a look at their extremely bullish case:
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.